| Therapeutics |
Diagnostics |
|
Currently represent over 80 therapeutics companies, including:
Acucela, Inc.
Alnylam Pharmaceuticals
Ambit Biosciences
Corium International
Novartis Vaccines and Diagnostics
OncoGenex Pharmaceuticals, Inc. |
Currently represent over 40 companies specializing in diagnostics, including:
CardioDx, Inc.
Cepheid
diaDexus, Inc.
Edwards Lifesciences Corporation
Natus Medical
OncoHealth Corporation |
| |
| Medical Devices |
Healthcare Information Technology |
Currently represent over 60 medical device companies, including:
Ambu
Cardiac Science, Corp.
DexCom, Inc.
ForteBio, Inc.
SonoSite, Inc.
The Cooper Companies |
Currently represent over 45 health care IT companies, including:
Allscripts Healthcare Solutions
California Regional Health Information Organization
Cardinal Health
CareClarity, Inc.
McKesson HBOC Corporation
Medem, Inc.
Rothman Healthcare Research |
| |
| Industrial Biotech |
Academic and Research |
Currently represent 15 industrial biotechnology companies, including:
Amyris
Bio Architecture Labs
Genencor International
Joule Unlimited
Mendel Biotechnology
Novozymes North America
|
Currently represent over 30 academic and research institutions on their life sciences matters, including:
Charles River Laboratories
Emory University
Los Alamos National Laboratory
Oregon Health & Sciences University
The Scripps Research Institute
University of Washington |
| |
| Bioinformatics and Software |
Investors |
Currently represent over 15 companies specializing in bioinformatics, including:
Applied Biocomputing
Alpha Innotech Corporation
Lightspeed Genomics
Primity Bio, Inc.
Simprota Corporation
Viral Logic Systems Technology |
Currently advise over 20 investment funds on life sciences matters, including:
California Technology Ventures
Clarus Ventures
Mohr Davidow
New Enterprise Associates
Xseed Capital |
| |
| Private/VC Backed |
1934 Act Reporting |
Currently represent 70+ VC-backed life sciences clients (and more than 400 venture capital and private equity-backed private companies across all industries), including:
Acucela, Inc.
Broncus Technologies, Inc.
Cardiac Dimensions, Inc.
Corium International, Inc.
ForteBio, Inc.
Mendel Biotechnology |
Currently represent over 10 companies as outside securities counsel, including:
Amyris, Inc.
DexCom, Inc.
Natus Medical, Inc.
OncoGenex Pharmaceuticals, Inc.
Solta Medical, Inc.
SonoSite, Inc. |
| |
| M&A |
Patent |
Currently advise over 25 life sciences companies with mergers and acquisitions matters:, including:
Cepheid
Natus Medical, Inc.
Peplin, Inc.
Solta Medical, Inc.
SonoSite, Inc.
Teikoku Pharma USA |
Currently represent over 130 life sciences patent clients, including:
Alnylam Pharmaceuticals
APT Pharmaceuticals
CadioDx, Inc.
Ernest Gallo Clinic
ForteBio, Inc.
Presidio Pharmaceuticals |
| |
| Licensing |
Trademark |
Currently advise over 50 life sciences companies with their licensing needs, including:
CFD Therapeutics
DexCom, Inc.
Medicity, Inc.
Natus Medical, Inc.
Novartis Vaccines and Diagnostics
PolyRemedy, Inc. |
Currently advise over 40 life sciences companies with their trademark needs, including:
Abbott Vascular
Conceptus, Inc.
McKesson Corp.
Mountain View Pharmaceuticals
Reviva Pharmaceuticals
Satori Labs, Inc. |
| |
| IP Litigation |
Tax |
Currently represent over 25 life sciences companies on IP litigation matters, including:
Ambu
Canada Drugs.com
Cardiac Science Corp.
DexCom, Inc.
Novartis Vaccines and Diagnostics
Novozymes A/S |
Currently advise over 30 life sciences companies on tax matters, including:
Abbott Laboratories
Albany Molecular Research
Carestream Health
Endo Pharmaceuticals
Sanofi-Aventis US
Valeant Pharmaceuticals International |
Representative Transactions
Represented Allozyne in its reverse merger with Poniard Pharmaceuticals (pending)
Represented Natus Medical in its $150M shelf offering
Represented Medicity in its $500M acquisition by Aetna
Represented Solta Medical in its acquisition of CLRA Technology
Represented Amyris in its $84.8M initial public offering
Represented Asthmatx in its $443M acquisition by Boston Scientific
Represented ZymoGenetics in its acquisition by Bristol-Meyers Squibb
Represented Trubion in its $96M acquisition by Emergent BioSolutions
Represented Axolotl Corporation in its acquisition by Ingenix
Represented SonoSite in its $71M acquisition of Visualsonics
Represented LipoSonix in its $300M acquisition by Medicis Pharmaceutical
Represented Peplin in its $287.5M acquisition by LEO Pharma – the highest price ever paid for a pre-FDA approved company
Represented Connetics Corporation in its $930M acquisition by Stiefel Laboratories
Represented Ocular Sciences in its $1.2B acquisition by The Cooper Companies
Representative Patent and Securities Litigation
Patent Litigation
- Novozymes v. Genencor. Represented Novozymes as lead trial counsel asserting patent on genetically modified alpha-amylases. Genencor was found to willfully infringe and ordered to pay double damages and attorneys' fees.
- E.I. du Pont de Nemours & Co. v. Cetus Corporation. Represented Cetus in obtaining a jury verdict upholding the validity of patents for its Nobel Prize-winning polymerase chain reaction and later a consent injunction precluding du Pont's further infringement.
- Elan Pharmaceuticals v Mayo Foundation. Represented Elan to enforce its patent on transgenic mice for the study of Alzheimer's disease. After establishing that the desired transgenic mice could not be made and identified without the essential inventive discovery of the Elan scientists, the patents' validity were upheld on appeal and Elan was able to successfully license them to the principal source of competing transgenic mice, the Mayo Foundation.
- Bausch & Lomb v. CooperVision: Represent CooperVision in a patent infringement case brought by Bausch & Lomb in the Western District of NY relating to contact lenses. Shortly after obtaining a claim construction order highly favorable to CooperVision, the case was settled.
- Schering v. Glenmark. Representing Glenmark, the only challenger to Schering's ezetimibe patent covering $5 billion per year drug. Favorable settlement on the eve of trial followed a Glenmark summary judgment victory.
Securities Litigation
- Ongoing counseling to boards and management on disclosure, regulatory and litigation issues for leading life sciences companies such as Cepheid and DexCom.
- Defense of securities class action and SEC investigation of Connetics alleging inadequate disclosure of FDA communications and pre-clinical tests, improper revenue recognition and insider trading.
- Defense of the directors of drugstore.com (including John Doerr, Melinda Gates and Jeff Bezos) in a derivative action based on allegations of misrepresentations and insider trading. The case is currently pending in Washington state court.
- Defense of shareholder litigation challenging the acquisition of Connetics by Stiefel Laboratories.
- Represented Special Committee of the Affymetrix Board of Directors in federal and state derivative litigation.
|
